

Mr. Javier Ruiz del Pozo
Head of Secondary Markets
CNMV
Edison, 4
28006 Madrid

Barcelona, February 2, 2016

RELEVANT FACT

Dear Sir,

In accordance with Law 24/1988, of July 28, relative to the regulation of the stock markets and related provisions, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), submits hereafter press release on the acquisition to Chiesi Spain SA of a sodium heparin.

Yours faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA

Acquisition to Chiesi España SA

REIG JOFRE STRENGTHENS ITS PORTFOLIO OF STERILE INJECTABLE PRODUCTS WITH THE ACQUISITION OF A SODIUM HEPARIN

- Sodium heparin is an injectable anticoagulant extensively used in clinical medicine, especially in dialysis and surgery.
- Reig Jofre has a commercial network in Spain of 105 sales representatives, specialized among others in the hospital channel.
- Reig Jofre will be the second largest supplier of sodium heparin in Spain, with a market share of 20% and estimated revenues of € 0.75 million in 2016.

Barcelona (Spain), February 2, 2016. Pharmaceutical company Reig Jofre has acquired to Chiesi España SA a sodium heparin and its marketing authorization for Spain.

Sodium heparin is an antithrombotic medicine with anticoagulant action in injectable solution. In Spain, 3 million units are sold annually, of which 66% in hospitals -mainly for dialysis, and a smaller percentage to other services such as transplants and surgeries-, and 33% in private dialysis centers.

Reig Jofre has a commercial network in Spain of 105 sales representatives, specialized among others in the hospital channel. Through this acquisition, Reig Jofre will be the second largest supplier of sodium heparin, a product of consolidated presence in the Spanish market, which will give the company a market share of 20% upon a starting point of 600,000 units sold in 2015.

The acquisition was financed with Reig Jofre's own resources and will bring the company estimated revenues of € 0.75 million in 2016.

The specialization in sterile injectable generics for hospitals, mostly developed by Reig Jofre's R&D teams, is one of the spearheads of the internationalization of the company. Reig Jofre generates 60% of its turnover outside Spain, through direct sales in 6 countries in Europe and the licensing of dossiers to a network of over 100 partners in 50 countries worldwide.



The acquisition reinforces Reig Jofre's will to combine organic growth with acquisitions in the company's strategic areas.

Reig Jofre closed 2014 (last year reported) with sales of € 152.5 million and net profit of € 6.9 million.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the marketing and manufacture of own developments (RJF Pharma, approximately 78% of sales in 2014) and one of specialized contract development and manufacturing (RJF CDMO, 22% of sales in 2014). At its core activity, the company focuses on the development of specialised-technology products (antibiotics and injectable); therapeutic-specialty products in the areas of dermatology, gynaecology and respiratory; and nutritional supplements and consumer healthcare. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generic medicines with a special focus on beta-lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements as well as the development of new innovative molecules in partnership with start-ups and research centres.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 63,214,220.

For further information

Investors and analysts

Gloria Folch
Head of Investor Relations
REIG JOFRE
Tel. +34 93 480 67 10 – ext. 1241
gloria.folch@reigjofre.com

Media

Ricardo Franco
ATREVIA
Tel. +34 93 419 06 30
rfranco@atrevia.es